Factors to consider in sequencing of tafasitamab

Tafasitamab targets CD19, and epcoritamab targets CD20 and CD3, bringing T cells into close contact with the lymphoma cells, Poh notes. Tafasitamab can certainly be used before a bispecific, and in selected patients that may be a very reasonable approach. But the reverse is also possible because of the differences in the mechanism of action, she says. Poh says the data are lacking that would provide the evidence needed to be certain about which one should come first and that it comes down to individual disease risk, prior therapy and patient comorbidities.